Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 260

1.

Author Correction: Mitochondrial metabolism promotes adaptation to proteotoxic stress.

Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, Thiru P, Reidy M, Kugener G, Rossen J, Kocak M, Kory N, Tsherniak A, Santagata S, Whitesell L, Ghobrial IM, Markley JL, Lindquist S, Golub TR.

Nat Chem Biol. 2019 Jul;15(7):757. doi: 10.1038/s41589-019-0315-5.

PMID:
31164776
2.

Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies.

Lee DH, Fung TT, Tabung FK, Colditz GA, Ghobrial IM, Rosner BA, Giovannucci EL, Birmann BM.

JNCI Cancer Spectr. 2019 Jun;3(2):pkz025. doi: 10.1093/jncics/pkz025. Epub 2019 Apr 27.

3.

A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.

Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, Jakubowiak A, Savona MR, Obreja M, Berdeja JG.

Clin Cancer Res. 2019 May 29. doi: 10.1158/1078-0432.CCR-18-3728. [Epub ahead of print]

PMID:
31142508
4.

Mitochondrial metabolism promotes adaptation to proteotoxic stress.

Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, Thiru P, Reidy M, Kugener G, Rossen J, Kocak M, Kory N, Tsherniak A, Santagata S, Whitesell L, Ghobrial IM, Markley JL, Lindquist S, Golub TR.

Nat Chem Biol. 2019 Jul;15(7):681-689. doi: 10.1038/s41589-019-0291-9. Epub 2019 May 27. Erratum in: Nat Chem Biol. 2019 Jun 4;:.

PMID:
31133756
5.

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):332-344. doi: 10.1016/j.clml.2019.02.004. Epub 2019 Feb 20. Review.

PMID:
31023594
6.

Monoclonal gammopathy of undetermined significance.

Mouhieddine TH, Weeks LD, Ghobrial IM.

Blood. 2019 Jun 6;133(23):2484-2494. doi: 10.1182/blood.2019846782. Epub 2019 Apr 22. Review.

PMID:
31010848
7.

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM.

J Clin Oncol. 2019 Jun 1;37(16):1403-1411. doi: 10.1200/JCO.19.00394. Epub 2019 Apr 16.

PMID:
30990729
8.

Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.

Sahin I, Kawano Y, Sklavenitis-Pistofidis R, Moschetta M, Mishima Y, Manier S, Sacco A, Carrasco R, Fonseca R, Roccaro AM, Witzig T, Ghobrial IM.

Blood Adv. 2019 Apr 9;3(7):995-1002. doi: 10.1182/bloodadvances.2018028456.

9.

Kidney micro-organoids in suspension culture as a scalable source of human pluripotent stem cell-derived kidney cells.

Kumar SV, Er PX, Lawlor KT, Motazedian A, Scurr M, Ghobrial I, Combes AN, Zappia L, Oshlack A, Stanley EG, Little MH.

Development. 2019 Mar 7;146(5). pii: dev172361. doi: 10.1242/dev.172361.

10.

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, Dimopoulos MA.

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6. No abstract available.

PMID:
30773670
11.

3D organoid-derived human glomeruli for personalised podocyte disease modelling and drug screening.

Hale LJ, Howden SE, Phipson B, Lonsdale A, Er PX, Ghobrial I, Hosawi S, Wilson S, Lawlor KT, Khan S, Oshlack A, Quinlan C, Lennon R, Little MH.

Nat Commun. 2018 Dec 4;9(1):5167. doi: 10.1038/s41467-018-07594-z.

12.

Autologous graft versus myeloma: it's not a myth.

Dong S, Ghobrial IM.

J Clin Invest. 2019 Jan 2;129(1):48-50. doi: 10.1172/JCI125431. Epub 2018 Nov 19.

13.

Triply Loaded Nitroxide Brush-Arm Star Polymers Enable Metal-Free Millimetric Tumor Detection by Magnetic Resonance Imaging.

Nguyen HV, Detappe A, Gallagher NM, Zhang H, Harvey P, Yan C, Mathieu C, Golder MR, Jiang Y, Ottaviani MF, Jasanoff A, Rajca A, Ghobrial I, Ghoroghchian PP, Johnson JA.

ACS Nano. 2018 Nov 27;12(11):11343-11354. doi: 10.1021/acsnano.8b06160. Epub 2018 Nov 2.

14.

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM.

Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26. No abstract available.

PMID:
30366921
15.

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.

Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M.

PLoS One. 2018 Oct 4;13(10):e0204589. doi: 10.1371/journal.pone.0204589. eCollection 2018.

16.

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.

Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin M, Reynolds C, Shain KH, Zackon I, Stampleman L, Henrick P, Rivotto B, Hornburg KTV, Dumke HJ, Chuma S, Savell A, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM.

Clin Cancer Res. 2019 Jan 15;25(2):478-486. doi: 10.1158/1078-0432.CCR-18-1325. Epub 2018 Oct 2.

PMID:
30279233
17.

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.

Aldoss I, Capelletti M, Park J, Pistofidis RS, Pillai R, Stiller T, Sanchez JF, Forman SJ, Ghobrial IM, Krishnan A.

Leukemia. 2019 Jan;33(1):266-270. doi: 10.1038/s41375-018-0213-y. Epub 2018 Jul 19.

PMID:
30026571
18.

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.

Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thrue CA, Nagano K, Petri A, Roccaro AM, Capelletti M, Baron R, Kauppinen S, Ghobrial IM.

Leukemia. 2018 Aug;32(8):1739-1750. doi: 10.1038/s41375-018-0161-6. Epub 2018 Jun 20.

PMID:
29925904
19.

Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation.

Cheng MP, Pandit A, Antin JH, Walsh SR, Huynh D, Ghobrial IM, Baden LR, Marty FM, Issa NC.

Blood Adv. 2018 Jun 12;2(11):1272-1276. doi: 10.1182/bloodadvances.2018018911. Erratum in: Blood Adv. 2018 Jul 10;2(13):1541.

20.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS.

Br J Haematol. 2018 Jul;182(2):222-230. doi: 10.1111/bjh.15261. Epub 2018 May 8.

Supplemental Content

Loading ...
Support Center